Great Bay Bio 大湾生物

Great Bay Bio (GBB), headquartered in HKSTP, is a biotech company that drives drug development using cutting-edge technologies such as AI, big data mining, and automation. GBB adheres to the corporate vision of "Global Bioprocessing Made Simpler and More Efficient," and aims to address the challenges of long timelines, high costs, and low success rates in drug development, with a long-term goal of enhancing human life, health, and value. The core team of GBB comprises experts from medicine, synthetic biology, and artificial intelligence. The company operates a R&D laboratory and CMC platform, supporting customers in securing clinical trial approvals from China’s NMPA and the US FDA. GBB has secured nearly 100 patents related to AI-enabled drug development and successfully commercialized multiple AI technology platforms. The company has established long-term partnerships with leading domestic and international enterprises. GBB has passed the ISO 9001:2015 quality management system certification, been selected for Forbes Asia 100 to Watch 2024 List, and won numerous awards, including "Deloitte Technology Rising Star Company,""EY Entrepreneur Of The Year,""15th Shenzhen Innovation & Entrepreneurship Competition,""Gold Award for Hong Kong Global Innovation,""Excellence in Process Innovation Award," and "Excellence in Technology Adoption Award". The company has also been successfully selected for the Hong Kong Science Park Elite Enterprise Program.